TRP2 peptide-pulsed dendritic cells

TRP2 peptide-pulsed dendritic cells are an autologous cellular immunotherapy designed to treat melanoma and other TRP2-expressing malignancies. The therapeutic process involves isolating a patient's monocytes, differentiating them into dendritic cells (DCs) ex vivo, and loading (pulsing) them with peptides derived from Tyrosinase-related protein 2 (TRP2), also known as L-dopachrome tautomerase. TRP2 is a melanocyte-specific enzyme that is highly conserved and frequently overexpressed in melanoma cells, making it a viable tumor-associated antigen. Once matured and antigen-loaded, these DCs are re-administered to the patient, where they migrate to secondary lymphoid organs to present TRP2 epitopes to naive T cells. This interaction triggers the activation and expansion of TRP2-specific CD8+ cytotoxic T lymphocytes (CTLs), which are then capable of recognizing and lysing tumor cells that express the TRP2 antigen. This approach leverages the potent antigen-presenting capacity of dendritic cells to overcome immune tolerance and generate a targeted anti-tumor response.

Other names

TRP-2-pulsed dendritic cell vaccineTRP2-pulsed dendritic cell vaccineTRP 2-pulsed dendritic cell vaccineTyrosinase-related protein 2-pulsed dendritic cellsTRP2-pulsed DC vaccineTRP-2-pulsed DC vaccineTRP 2-pulsed DC vaccine